These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20191449)

  • 1. [The results of the TREAT study: lessons and limitations].
    Del Vecchio L
    G Ital Nefrol; 2010; 27(1):3. PubMed ID: 20191449
    [No Abstract]   [Full Text] [Related]  

  • 2. The TREAT study answers a question, not the question.
    Coyne DW
    Am J Kidney Dis; 2008 Sep; 52(3):626-7; author reply 627-8. PubMed ID: 18725019
    [No Abstract]   [Full Text] [Related]  

  • 3. Anemia normalization in patients with type 2 diabetes and chronic kidney disease: results of the NEPHRODIAB2 randomized trial.
    Villar E; Lièvre M; Kessler M; Lemaître V; Alamartine E; Rodier M; François M; Zaoui P; Moranne O; Choukroun G; Guerraoui A; Jolivot A; Janin G; Branger B; Heng AE; Boudray C; Bissery A; Rabilloud M; Pouteil-Noble C
    J Diabetes Complications; 2011; 25(4):237-43. PubMed ID: 21601481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA).
    Goldsmith D; Covic A
    Nephrol Dial Transplant; 2010 Jun; 25(6):1734-7. PubMed ID: 20200007
    [No Abstract]   [Full Text] [Related]  

  • 5. Anemia: To TREAT or not to TREAT--that is the question.
    Wiecek A
    Nat Rev Nephrol; 2010 May; 6(5):254-5. PubMed ID: 20424627
    [No Abstract]   [Full Text] [Related]  

  • 6. No TREATment with darbepoetin dosed to hemoglobin 13 grams per deciliter in type 2 diabetes with pre-dialysis chronic kidney disease--safety warnings for erythropoiesis-stimulating agents.
    Curtiss FR; Fairman KA
    J Manag Care Pharm; 2009; 15(9):759-65. PubMed ID: 19954267
    [No Abstract]   [Full Text] [Related]  

  • 7. Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients?
    Berns JS
    Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):567-72. PubMed ID: 20601876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The "forgotten adjunct therapy": the link between ESA use and control of hyperparathyroidism in chronic kidney disease.
    Battistella M; Chan CT
    Semin Dial; 2013; 26(5):537-40. PubMed ID: 23734745
    [No Abstract]   [Full Text] [Related]  

  • 9. Erythropoietin: high profile, high scrutiny.
    Crawford J
    J Clin Oncol; 2007 Mar; 25(9):1021-3. PubMed ID: 17312331
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
    Leszek P; Kruszewski M
    Eur Heart J; 2008 Feb; 29(4):565-6; author reply 566-7. PubMed ID: 18192702
    [No Abstract]   [Full Text] [Related]  

  • 11. More than a decade of experience and still no consensus: controversies in iron therapy.
    Besarab A
    Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S1-3. PubMed ID: 17699371
    [No Abstract]   [Full Text] [Related]  

  • 12. Erythropoiesis-stimulating agents--time for a reevaluation.
    Unger EF; Thompson AM; Blank MJ; Temple R
    N Engl J Med; 2010 Jan; 362(3):189-92. PubMed ID: 20054037
    [No Abstract]   [Full Text] [Related]  

  • 13. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
    Singh AK
    J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
    [No Abstract]   [Full Text] [Related]  

  • 14. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.
    Steensma DP
    J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of anemia in chronic kidney disease--strategies based on evidence.
    Marsden PA
    N Engl J Med; 2009 Nov; 361(21):2089-90. PubMed ID: 19880845
    [No Abstract]   [Full Text] [Related]  

  • 16. Anaemia management in cardio renal disease.
    Silverberg DS; Wexler D; Iaina A; Schwartz D
    J Ren Care; 2010 May; 36 Suppl 1():86-96. PubMed ID: 20586904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trick or TREAT? More condemning evidence against ESAs.
    Zarowitz BJ
    Geriatr Nurs; 2010; 31(1):52-4. PubMed ID: 20159353
    [No Abstract]   [Full Text] [Related]  

  • 18. Erythropoietins should be used according to guidelines.
    Aapro MS; Birgegård G; Bokemeyer C; Cornes P; Foubert J; Gascon P; Glaspy J; Hellström-Lindberg E; Link H; Ludwig H; Osterborg A; Repetto L; Soubeyran P
    Lancet Oncol; 2008 May; 9(5):412-3. PubMed ID: 18452853
    [No Abstract]   [Full Text] [Related]  

  • 19. The FDA black box for EPO: what should nephrologists do?
    Singh AK
    Nephrol News Issues; 2007 May; 21(6):55-6, 58-9. PubMed ID: 17518125
    [No Abstract]   [Full Text] [Related]  

  • 20. [Interview with professor Thierry Hannedouche].
    Hannedouche T
    Nephrol Ther; 2006 May; 2 Suppl 3():S200-2. PubMed ID: 17370852
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.